Regulatory Blog

The European regulatory landscape continues to evolve with a strong focus on supporting innovation in rare diseases and ensuring safe, evidence-based development of medicines for children . The European Medicines Agency (EMA) has issued two key procedural guidelines: Procedural advice for orphan medicinal product designation – Guidance for sponsors Procedural advice on paediatric applications – Guidance for applicants together, establish a comprehensive regulatory framewo